PE20020219A1 - Derivados de 6-fenilpirrolpirimidindiona como inhibidores de fosfodiesterasa 5 - Google Patents

Derivados de 6-fenilpirrolpirimidindiona como inhibidores de fosfodiesterasa 5

Info

Publication number
PE20020219A1
PE20020219A1 PE2001000521A PE2001000521A PE20020219A1 PE 20020219 A1 PE20020219 A1 PE 20020219A1 PE 2001000521 A PE2001000521 A PE 2001000521A PE 2001000521 A PE2001000521 A PE 2001000521A PE 20020219 A1 PE20020219 A1 PE 20020219A1
Authority
PE
Peru
Prior art keywords
diona
dihydropyrrol
phenyl
derivatives
propoxifenil
Prior art date
Application number
PE2001000521A
Other languages
English (en)
Inventor
Ferrer Jordi Gracia
Juan Bernat Vidal
Noverola Armando Vega
Soto Jose Manuel Prieto
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of PE20020219A1 publication Critical patent/PE20020219A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A DERIVADOS DE 6-(DISUSTITUIDOS)FENIL-1,5-DIHIDROPIRROL[3,2-d]PIRIMIDIN-2,4-DIONA; 6-(DISUSTITUIDO)FENIL-1,7-DIHIDROPIRROL[2,3-d]-PIRIMIDIN-2,4-DIONA DE FORMULA I DONDE -X-C-Y- ES -NH-CH=CR6-, -CR6=CH-NH-; R1, R2, R3 SON H, ALQUILO, ENTRE OTROS; n ES 0-4; R7 ES CICLOALQUILO, FENILO, ENTRE OTROS; R4 Y R5 SON H, ALQUILO O JUNTO A N FORMAN UN ANILLO DE 3-7 MIEMBROS CON 1-4 HETEROATOMOS; R4 ES H, ALQUILO Y R5 ES (CH2)n-R7; R6 ES H, HALOGENO, NITRO, ALCOXICARBONILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 3-.METIL-6-[5-(4-METILPIPERACIN-1-SULFONIL)-2-PROPOXIFENIL]-1-PROPIL-1,5-DIHIDROPIRROL[3,2-d]PIRIMIDIN-2,4-DIONA; 6-[5-(4-ETILPIPERACIN-1-SULFONIL)-2-PROPOXIFENIL]-3-METIL-1-PROPIL-1,5-DIHIDROPIRROL[3,2-d]PIRIMIDIN-2,4-DIONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. EL COMPUESTO ES INHIBIDOR DEGMP CICLICO FOSFODIESTERASA 5 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ANGINA, HIPERTENSION, FALLO CARDIACO CONGESTIVO, FALLO RENAL, ATEROSCLEROSIS, ENFERMEDAD VASCULAR PERIFERICA, TRASTORNOS VASCULARES, DISFUNCION SEXUAL
PE2001000521A 2000-06-07 2001-06-06 Derivados de 6-fenilpirrolpirimidindiona como inhibidores de fosfodiesterasa 5 PE20020219A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200001436 2000-06-07

Publications (1)

Publication Number Publication Date
PE20020219A1 true PE20020219A1 (es) 2002-04-17

Family

ID=8493813

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000521A PE20020219A1 (es) 2000-06-07 2001-06-06 Derivados de 6-fenilpirrolpirimidindiona como inhibidores de fosfodiesterasa 5

Country Status (12)

Country Link
US (1) US6943253B2 (es)
EP (1) EP1286997B1 (es)
JP (1) JP2003535864A (es)
AR (1) AR030424A1 (es)
AT (1) ATE273980T1 (es)
AU (1) AU2001281802A1 (es)
CA (1) CA2411013A1 (es)
DE (1) DE60105020T2 (es)
ES (1) ES2222389T3 (es)
MY (1) MY133995A (es)
PE (1) PE20020219A1 (es)
WO (1) WO2001094350A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
ES2208063B1 (es) 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
US20070010450A1 (en) * 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
ATE419252T1 (de) 2003-10-31 2009-01-15 Cv Therapeutics Inc Antagonisten des a2b-adenosinrezeptors
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AR077898A1 (es) * 2009-08-26 2011-09-28 Nycomed Gmbh Metilpirrolopirimidincarboxamidas
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
AT512084A1 (de) * 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
WO2016126929A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
JP2018504432A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
US20030232838A1 (en) 2003-12-18
ES2222389T3 (es) 2005-02-01
AR030424A1 (es) 2003-08-20
CA2411013A1 (en) 2001-12-13
WO2001094350A1 (en) 2001-12-13
EP1286997A1 (en) 2003-03-05
MY133995A (en) 2007-11-30
JP2003535864A (ja) 2003-12-02
ATE273980T1 (de) 2004-09-15
EP1286997B1 (en) 2004-08-18
DE60105020T2 (de) 2005-08-18
AU2001281802A1 (en) 2001-12-17
DE60105020D1 (de) 2004-09-23
US6943253B2 (en) 2005-09-13

Similar Documents

Publication Publication Date Title
PE20020219A1 (es) Derivados de 6-fenilpirrolpirimidindiona como inhibidores de fosfodiesterasa 5
EA200600315A1 (ru) Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
PE20060600A1 (es) Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa
PE20050681A1 (es) PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
CO5060482A1 (es) Derivados terapeuticos de biarilo
RU2007143966A (ru) Конденсированные гетероциклические соединения
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
NO20045282L (no) Inhibitorer av Jak-proteinkinase
ATE145208T1 (de) Kondensierte thiophenverbindungen und deren verwendung
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
PE20011287A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
PE20030940A1 (es) Derivados de piridina y pirimidina
DE60219672D1 (de) Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften
PE20061078A1 (es) Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4)
PE20011008A1 (es) Derivados de pirimidina como inhibidores de ciclooxigenasa 2
ATE461192T1 (de) Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung
PE20080534A1 (es) Compuestos derivados de piridinas y piridazinas sustituidos como inhibidores de kdr
JP2007501210A5 (es)
DE60326933D1 (de) Kondensierte bicyclische pyrimidinderivate
UA87895C2 (en) Substituted 5-phenyl pyrimidines i in therapy
JO2307B1 (en) Papermidine derivatives
DE60009544D1 (de) Il-8 rezeptor antagonisten

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed